Acacia Pharma (EU: ACPH)

Last close As at 27/03/2024

1.28

0.04 (3.23%)

Market capitalisation

129m

Edison Investment Research is terminating coverage on Acacia Pharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

Acacia Pharma — Progressing on all-important formulary wins

Healthcare | Update

Acacia Pharma — BARHEMSYS and BYFAVO launched in the US

Healthcare | Update

Acacia Pharma — Two US drug launches in 2020

Healthcare | Update

Acacia Pharma — BYFAVO receives FDA approval

Share Price Performance

Financials

Acacia Pharma has updated the market on the significant ongoing progress of US formulary wins for BARHEMSYS for the treatment and prevention of post-operative nausea and vomiting (PONV) and BYFAVO, an intravenous sedative for use during invasive medical procedures. Formulary access is key for initial sales in the hospital setting and early BARHEMSYS sales should start to trickle through by end FY21/early FY22, while the focus for BYFAVO remains on formulary wins. Obtaining wide formulary adoption is critical and should translate to significant revenue generation from FY22 and maiden operating profit from FY23. Our valuation of Acacia Pharma is unchanged at €1,278m.

Research

Update

Healthcare

Acacia Pharma — BYFAVO receives FDA approval

Update

Healthcare

Acacia Pharma — Next catalyst ByFavo PDUFA date

Update

Healthcare

Acacia Pharma — Preparing for US BARHEMSYS launch

Update

Healthcare

Acacia Pharma — FDA approves BARHEMSYS for PONV

Update

Healthcare

Acacia Pharma — Cosmo provides cash injection

Flash note

Healthcare

Acacia Pharma — ByFavo deal to bolster pipeline

Flash note

Healthcare

Acacia Pharma — BARHEMSYS round three PDUFA date

Flash note

Healthcare

Acacia Pharma — NDA resubmission before month-end

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free